Early to Progressive Metastatic Stage 4 Effect of Standard Therapy in Various Stages
Up to 2.3 times progression-free survival, 83% reduction in risk of recurrence and death
Tagriso (ingredient name osimertinib), a third-generation EGFR mutant non-small cell lung cancer target treatment, has been launched for 5 years.
Tagriso was evaluated for changing the paradigm of non-small cell lung cancer treatment, and recently, it was the first drug of the same line to be approved as an adjuvant therapy after surgery.
AstraZeneca, a manufacturer and seller, held a press conference to commemorate the 5th anniversary of its launch on the 19th and introduced the results of three phase 3 clinical trials, revealing its footsteps and will open a new horizon for future treatment.
Chief Researcher Han Ji-yeon of the National Cancer Center introduced the results of the landmark study AURA3 and FLAURA on the day. According to AURA3, the progression-free survival (median) was 10.1 months, more than twice that of standard therapy.
FLAURA was also extended by 8.7 months to 18.9 months, and the overall survival period was 38.6 months, which was superior to standard therapy (31.8 months).
Professor Hong Min-hee of Severance Cancer Hospital also introduced the results of the latest clinical trial ADAURA, which showed that disease-free survival, recurrence, and mortality risk decreased 83% compared to placebo at 24 months of administration.
Professor Hong also said that the recurrence rate of early lung cancer within 5 years of tumor resection was 50%, and that Tagrisso reduced the risk of recurrence and death in stage 1~3 lung cancer patients by 80% compared to placebo.
“With these remarkable outcomes, the American Society of Clinical Cancer (ASCO) recommended early release of clinical data by an independent data monitoring committee.” “We will open a new horizon for lung cancer treatment in the future.”
Currently, the National Cancer Network (NCCN) guidelines recommend tagriso as the only preferred therapy, even at the highest recommended level (category 1) in the first-line treatment of EGFR mutant non-small cell lung cancer patients.
In addition, it was recommended as Category 1 for second-line treatment, and chemotherapy and tagriso treatment are recommended as an adjuvant therapy for early stage non-small cell lung cancer that can be operated.
Copyright © Medical Tribune Unauthorized reproduction and redistribution prohibited